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Abstract
Background and Aims Treatment pathways for ulcerative colitis (UC) and Crohn’s disease (CD) are shifting to a more 
individualized, risk-stratified approach. The perception is that insurance policies may not have implemented this paradigm 
shift, particularly regarding access to newer agents. We evaluated patient access to advanced therapies by analyzing policy 
information from the Managed Markets Insight and Technology database.
Methods Coverage status as of December 2018 for all US lives was queried for adalimumab, infliximab, infliximab-dyyb, 
tofacitinib, ustekinumab, and vedolizumab by indication (UC and/or CD) and medical or pharmacy coverage benefit. Cover-
age status was classified by the number of biologic steps before access to specified drug as “No Biologic,” “1 Prior Biologic,” 
“2+ Prior Biologics,” “Not Covered.” Unknown lives were excluded from the analyses.
Results Coverage analysis was available for approximately 302 million lives under each medical and pharmacy benefit. Our 
analysis indicates that approximately half of covered lives had access to all agents (except tofacitinib) as first-line therapy; 
two-thirds had access after one biologic exposure. Among newer agents, vedolizumab had the widest coverage. For indica-
tions of UC and CD, 81% of known lives had access to vedolizumab with no prior biologic exposure required (“No Biologic”), 
95% after “No Biologic” + “1 prior Biologic.” Geographic variations were identified for coverage patterns.
Conclusions This US-based healthcare policy analysis points to an increased access to advanced therapies for UC and CD. 
An individualized, risk-stratified treatment approach integrating advanced therapies, including those recently approved, into 
treatment pathways for UC and CD is feasible.
Keywords Ulcerative colitis · Crohn’s disease · Health insurance coverage · Vedolizumab · Ustekinumab · Tofacitinib
Introduction
The goal of inflammatory bowel disease (IBD) manage-
ment is to induce and maintain corticosteroid-free clinical 
and endoscopic remission, while minimizing disease- and 
treatment-related adverse events [1–3]. To achieve this goal, 
treatment strategies have traditionally followed a step-up Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1062 0-019-05594 -7) contains 
supplementary material, which is available to authorized users.
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approach, in which patients are required to fail multiple 
immunosuppressive agents before starting a biologic agent 
[1, 3]. However, this step-up approach may not represent the 
optimal strategy, given that using agents with low efficacy 
for a prolonged duration allows inflammation to continue 
and tissue damage to occur [4]. Updated treatment guide-
lines supported by the American Gastroenterological Asso-
ciation (AGA) have evolved toward an individualized, risk-
stratified therapeutic approach, with the early integration of 
biologic therapy for high-risk patients [5–7]. As a result, 
biologic drugs are becoming the standard of care given their 
favorable efficacy and safety profiles compared with immu-
nomodulators [8].
The ability to use biologic therapies in clinical practice, 
however, is in part dictated by insurance company policies 
and their specification of preferred agents. A survey pub-
lished in 2017 of the 125 largest US insurance companies 
found that over 90% of policies were not compliant with 
the AGA clinical pathways for ulcerative colitis (UC) and 
Crohn’s disease (CD) [9]. Thus, healthcare coverage and 
access to therapy may not be consistent with treatment 
guidelines and recommendations. The gaps between cover-
age and optimal (or guideline-recommended) treatment may 
be more relevant for recently approved biologic therapies, 
as well as evolving small-molecule inhibitor therapies, and 
these gaps may affect the speed at which these therapies are 
adopted, regardless of their clinical benefit.
In recent years, the treatment landscape for IBD in the 
USA has seen several approvals of new agents beyond 
tumor necrosis factor (TNF) antagonists such as inflixi-
mab, infliximab biosimilars, and adalimumab. In 2014, the 
FDA approved vedolizumab, a humanized, gut-selective, 
monoclonal antibody that inhibits the migration of α4β7-
expressing T lymphocytes into the gut tissue, for use in adult 
patients with moderately to severely active UC and CD [10, 
11]. Subsequently, ustekinumab, a human monoclonal anti-
body against human interleukin 12 and interleukin 23 used 
for the treatment of moderately to severely active CD, and 
tofacitinib, a small-molecule inhibitor of the JAK1 and JAK3 
pathways for the treatment of moderately to severely active 
UC, were approved in 2016 and 2018, respectively [12, 13]. 
Each of these treatments has distinct clinical features, such 
as the potential safety advantages of being gut-selective for 
vedolizumab [14], or the convenience of oral administration 
for tofacitinib, that may make them attractive options, par-
ticularly for certain populations. Yet, it is unclear whether 
insurance coverage for these novel treatments as a first- or 
second-line agent is routinely approved in clinical practice. 
This uncertainty could have an impact on their appropriate 
integration into current treatment pathways, which has not 
been evaluated to date.
It would therefore be informative to more comprehen-
sively revisit the intention of the prior report [9] and reflect 
on whether there has been any progress in bringing together 
the recommendations from authoritative guidelines and the 
actual possibilities based on real-world access, especially 
now, with even more agents in the treatment armamentar-
ium. In this study, we evaluated patient access to advanced 
therapies overall, and to novel agents in particular, by ana-
lyzing policy information from the Managed Markets Insight 
and Technology (MMIT) LLC database.
Materials and Methods
Database Search
Data were extracted from the MMIT database, database as of 
December 18, 2018, and reported as number of lives covered 
under commercial, Medicare, state and managed Medicaid, 
and Health Exchanges. MMIT was chosen as a resource 
because of its extensive coverage of medical benefits and 
real-time assessments of approximately 3185 medical and 
6653 pharmacy benefit plans with nightly updates and rapid 
investigation into policy changes. The estimated proportions 
of plans represented in the MMIT database are approxi-
mately 82% local (defined as plans operating in 1 state), 
14% regional (defined as plans operating in 2–30 states), 
and 4% national (defined as plans operating in > 30 states). 
Of note, the percentage of plans within each category is not 
indicative of the number of lives contributed by each plan 
type. For this type of study, formal consent is not required.
Drug Access Calculation
Using MMIT’s Analytics 3 Web-based tool, coverage status 
as of December 18, 2018, for all US lives was queried for 
adalimumab, infliximab, infliximab-dyyb, tofacitinib, usteki-
numab, and vedolizumab by indication (UC and/or CD) and 
medical or pharmacy coverage benefit. To understand how 
coverage patterns varied among treatments administered by 
intravenous (IV) infusions, access was compared between 
TNF antagonist agents, including infliximab and an inf-
liximab biosimilar (infliximab-dyyb), vedolizumab, and 
ustekinumab (IV). These intravenous agents were covered 
primarily under the medical benefit, and therefore “medical 
coverage/lives” were used for access calculations. Adali-
mumab (subcutaneous [SC] injection), tofacitinib (oral), 
and ustekinumab (SC injection) are covered under pharmacy 
benefit; therefore, “pharmacy coverage/lives” were used for 
access calculations.
MMIT collects source documentation and determines 
coverage by digital collection methods (including digital 
stream from payers and pharmacy benefit managers, arti-
ficial intelligence to monitor payer-searchable sites, and 
published formulary documents) and manual collection 
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when needed. Through the manual process, MMIT collects 
formulary data via pdf and phone outreach from the payers 
when coverage cannot be confirmed via digital collection 
methods.
Coverage status for all drugs was assessed by MMIT’s 
team based on publicly available medical policies, prior 
authorization (PA), and pharmacy drug list documents. If 
these policies and/or documents are not publicly available 
for a plan, the coverage is classified as “Unknown,” “Cov-
ered (PA details unknown),” or “Covered (step therapy 
[ST] Details Unknown).” Lives with unknown coverage 
status arise from small regional plans that do not publicly 
publish detailed medical policies or from plans where 
prior authorization is specified on their formulary but 
coverage restriction details are unknown. When coverage 
status is known, all known lives were classified based on 
the number of prior biologic exposures before access to 
the specified drug as “No Biologic,” “1 prior Biologic,” 
“2+ prior Biologics,” and “Not Covered” (Fig. 1). The 
number of prior biologic exposures represents individual 
exposures of any biologic within the same or different 
class. An exposure could be a trial of, failure of, contrain-
dication to, or other interaction with a biologic, as defined 
by the insurance payer. A biologic therapy could include 
infliximab, adalimumab, ustekinumab, vedolizumab, goli-
mumab, certolizumab, or biosimilar infliximab, but the 
specific required biologic exposure is defined by the payer 
in the medical policy.
Regional Access Variations
To assess regional variations, coverage status for vedoli-
zumab (UC and CD indications combined), ustekinumab 
(CD only), and tofacitinib (UC only) was filtered by “No 
Biologic” and “No Biologic” + “1 prior Biologic” to identify 
the total number of covered lives by state. The numbers of 
lives were calculated at a state level using a weighted aver-
age and then adjusted for the census by dividing the number 
of covered lives by the July 2017 state census population. 
MMIT data represent 100% of the insured state populations. 
The methodology used takes into account census data for 
each state (to assign the total lives in each state), as well 
as the national uninsured rate (used to adjust each state’s 
population) and the AIS Health survey, which is the primary 
source of medical lives information.
Results
Overall Coverage
In total, 301,748,186 and 302,057,543 unique lives were 
captured in the MMIT database under the medical and phar-
macy benefit, respectively.
Overall, over 89% of lives required no or 1 prior biologic 
use (“No Biologic” + “1 prior Biologic”) before access to 
any of the drugs for the indications of UC or CD, with the 
Fig. 1  Methodology for drug 
market access determination. 
aUnknown and step therapy (ST 
Unknown) Status: Primarily for 
smaller regional plans (70% of 
unknown lives are from plans 
with < 300,000 lives). Managed 
Medicaid plans are most promi-
nent among these unknown 
statuses, followed by commer-
cial PPO plans. Typically, these 
types of smaller regional plans 
do not publicly publish detailed 
medical policies. bPrior Author-
ization (PA Unknown) Status: 
Plans where a PA is specified 
on their formulary; however, 
the details of the PA are not 
available and therefore cannot 
be assessed. PA restrictions are 
in place, but the details of those 
restrictions are unknown. PPO, 
preferred provider organization
Categorization Used for 
Calculating Access of Known 
Lives
No Biologic 
1 prior Biologic 
2+ prior Biologics 
Not Covered 
Excluded when calculating 
access of known lives
Not Covered 
Coverage Unknowna 
Covered (ST Details Unknown)a 
Covered (PA Details Unknown)b 
2+ Biologic Steps 
1 Biologic Step 
No Biologic Step 
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exception of tofacitinib (UC) and ustekinumab SC (CD), for 
which access was 68% and 71%, respectively (Fig. 2).
The products with wider coverage were infliximab and 
adalimumab. Access to infliximab and its biosimilar, inflix-
imab-dyyb, under the medical benefit was 95% and 89.8% 
(“No Biologic” + “1 prior Biologic”) for the indication of 
UC and 95% and 90% for the indication of CD, respectively. 
Adalimumab access under pharmacy benefit was 99% (“No 
Biologic” + “1 prior Biologic”) for the indications of UC 
and CD (Fig. 2).
Coverage of Novel Agents
Among newer agents, vedolizumab appeared to have the 
widest coverage. For the indications of UC and CD, 81% of 
known lives had access to vedolizumab with no prior bio-
logic exposure required (“No Biologic”), 95% after “No Bio-
logic” + “1 prior Biologic,” 4% after “2+ prior Biologics,” 
and 2% of lives had no coverage (Fig. 2). For the indication 
of UC, 43% of known lives had access to tofacitinib with 
no prior biologic exposure required (“No Biologic”), 68% 
after “No Biologic” + “1 prior Biologic,” 13% after “2+ prior 
Biologics,” and 19% of lives had no coverage. Ustekinumab 
coverage for the indication of CD varied based on the route 
of administration; ustekinumab IV was covered under medi-
cal benefit and ustekinumab SC under pharmacy benefit. 
Rate of coverage for ustekinumab SC was lower than for 
ustekinumab IV; 86% and 49% of known lives had access to 
ustekinumab IV and SC, respectively, without prior biologic 
exposure, and 94% and 71% after “No Biologic” + “1 prior 
Biologic.”
For the UC indication, ~ 7% and ~ 16% of lives had 
unknown coverage under medical and pharmacy benefit, 
respectively, and for the CD indication, unknown lives 
accounted for ~ 8% and ~ 7% under medical and pharmacy 
benefit, respectively.
When analyzed by type of insurance, vedolizumab and 
ustekinumab IV coverage without prior biologic exposure 
(“No Biologic”) was largely similar in commercial and gov-
ernment policies. Under pharmacy benefit, tofacitinib and 
ustekinumab SC coverage without prior biologic exposure in 
commercial policies was higher than in government policies. 
(Supplementary Data Contents 1–3).
Regional Variations in Coverage of Novel Agents
There was regional variability in access to all drugs evalu-
ated among states. Access rates were lowest for tofacitinib 
(10–44%) after “No Biologic” in all states for the UC indica-
tion (Fig. 3). Access was highest for vedolizumab after “No 
Biologic” + “1 prior Biologic,” with access rates > 60% in 
all states except for North Dakota, Mississippi, and Vermont 
for the UC and CD indications combined (Fig. 3).
Discussion
In the present analysis, more than 80% of covered lives 
had access to the newer biologics vedolizumab and usteki-
numab (IV) without any prior biologic exposure, and only 
4% or fewer lives were required to have an exposure to 
two or more biologics before having access. This biologic-
naïve access is consistent with the approved labeling for 
these agents, which indicates use after failure of conven-
tional therapy (corticosteroids, immunomodulators) [10, 
12]. These observations are in direct contrast to an analysis 
carried out in 2014 by Yadav et al., who, after analyzing 
the top 125 insurance policies by market share, concluded 
that only 11% and 8% of the first 50 reviewed policies 
covered vedolizumab without initial failure of a TNF 
antagonist in the UC and CD indications, respectively, 
and that 21% of policies required the failure of 2 or more 
TNF antagonists before covering vedolizumab. In the same 
analysis, 71% of policies allowed ustekinumab use without 
prior anti-TNF failure, although only 34% of the policies 
had a separate policy for ustekinumab [9]. We conducted 
our analysis in the same 50 policies, except for one that 
exited the insurance marketplace in 2015, and found cover-
age rates for vedolizumab to be higher than those reported 
in the Yadav et al. study. In fact, our data suggest that, of 
the 49 policies evaluated, 27 (55%) covered vedolizumab 
under “No Biologic” in the UC and CD indications (Sup-
plementary Data Content 4 and 5). In addition, 32 poli-
cies (65%) covered ustekinumab IV and 8 (16%) covered 
tofacitinib under “No Biologic” in the CD and UC indica-
tions, respectively (Supplementary Data Contents 4 and 5).
Of note, the Yadav analysis did not specify whether the 
plans included in the analysis were specific to the phar-
macy and/or medical benefit. Additionally, the plans in 
the Yadav analysis only accounted for ~ 171 million and 
~ 146 million lives under medical and pharmacy benefit, 
respectively, while this analysis captures ~ 302 million 
lives (under each medical and pharmacy benefit) and rep-
resents over ~ 6600 pharmacy plans and ~ 3200 medical 
plans. Overall, the observed shift in vedolizumab access 
since the Yadav et al. analysis may be a result of several 
factors including time-dependent limitations in integrat-
ing biologics within insurance policies and approval pro-
cesses, the evolution of clinical practice data to support the 
use of vedolizumab early in the biologic treatment cycle 
of patients, or enhanced understanding of vedolizumab 
cost-effectiveness.
These data may not reflect individual physician experi-
ence and, in fact, may be contrary to their personal under-
standing of access. It is worth noting the complex and 
sometimes convoluted steps between writing a prescrip-
tion and getting a drug to a patient. Benefit investigation, 
2482 Digestive Diseases and Sciences (2019) 64:2478–2488
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a
b
Fig. 2  Drug access under medical coverage for ulcerative colitis and 
Crohn’s disease. aApproximately 7% and 8% of lives had unknown 
coverage under medical benefit in UC and CD, respectively. bAp-
proximately 16% and 7% of lives had unknown coverage under phar-
macy benefit in UC and CD, respectively. cThe calculated percentage 
of covered lives excluded all unknown lives. dTofacitinib has a large 
percentage of unknown lives (~ 25%), primarily because it was only 
approved for UC in May 2018. Therefore, this may result in overin-
flection of the “No Biologic” coverage. CD, Crohn’s disease; MMIT, 
Managed Markets Insight and Technology; UC, ulcerative colitis 
Source: MMIT, December 18, 2018
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Fig. 3  Access for multiple drugs by state. a Vedolizumab UC and CD 
(No Biologic). Coverage for Alaska and Hawaii is 73% and 83%, respec-
tively. Source: MMIT, December 18, 2018. b Vedolizumab UC and 
CD (No Biologic + 1 prior Biologic). Coverage for Alaska and Hawaii 
is 73% and 86%, respectively. c Ustekinumab (IV) CD (No Biologic). 
Coverage for Alaska and Hawaii is 73% and 68%, respectively. d Usteki-
numab (IV) CD (No Biologic + 1 prior Biologic). Coverage for Alaska 
and Hawaii is 73% and 71%, respectively. e Ustekinumab (SC) CD (No 
Biologic). Coverage for Alaska and Hawaii is 26% and 49%, respec-
tively. f Ustekinumab (SC) CD (No Biologic + 1 prior Biologic). Cover-
age for Alaska and Hawaii is 41% and 52%, respectively. g Tofacitinib 
UC (No Biologic). Coverage for Alaska and Hawaii is 28% and 43%, 
respectively. h Tofacitinib UC (No Biologic + 1 prior Biologic). Cover-
age for Alaska and Hawaii is 39% and 49%, respectively
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employer plans, deductibles, vaccination, laboratory 
testing, X-rays, prior authorization paperwork, patient 
assistance programs, available infusion centers, specialty 
pharmacy requirements, and patient availability are all 
potential barriers that are often lumped into “access” 
issues. In addition, the regional variations show some 
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interesting data. Because many insurers rely on local phy-
sician demand to dictate policy changes, it may be difficult 
to determine whether local practices changed access or 
vice versa.
The ability of providers to use drugs in clinical practice 
is, in part, dictated by insurance company policies and their 
preferred agents. In an online survey of US gastroenter-
ologists, nearly half (44%) of physicians reported experi-
encing barriers to prescribing biologics for UC. The most 
commonly cited barrier was patient insurance restrictions 
(79%) [15]. Insurance coverage decisions are often based 
on a mix of unit cost, cost of administration, site of care, 
market share, manufacturer’s rebate, and positioning of an 
agent or portfolio of agents across multiple autoimmune 
disease indications. There are limited data and no published 
head-to-head trials to help inform drug positioning for IBD, 
although comparative effectiveness and safety studies have 
been conducted using real-world evidence to help bridge this 
gap [16, 17]. Results from a 2018 systematic review showed 
that infliximab and vedolizumab were ranked among the 
highest first-line agents for clinical remission and mucosal 
healing in patients with UC [18]. By leveraging their clinical 
expertise and knowledge of the risk–benefit profile of IBD 
treatment agents, physicians may be able to educate both 
patients and payers on the most appropriate agent for each 
patient. In addition, payers may designate some agents as 
their preferred agent without considering the relative safety, 
efficacy, cost, value, or optimal positioning. Introduction of 
agents to the marketplace with novel mechanisms of action 
or routes of administration is making traditional treatment 
paradigms obsolete. Many health plans are now allowing 
earlier access to more agents. Ideally these access changes 
will align with the emerging individualized, risk-stratified 
treatment approach.
Unlike vedolizumab and other infusion therapies that are 
primarily covered under the medical benefit, self-adminis-
tered injectables, such as adalimumab or ustekinumab SC, or 
oral drugs, such as tofacitinib, are primarily covered under 
the pharmacy benefit. Our results indicate that ustekinumab 
SC and tofacitinib access was lower than adalimumab. A 
possible explanation for this result could be the amount of 
time various treatments have been on the market, coverage 
for other indications driving larger rebates to health plans, 
or status as first-in-class treatment per formulation. Alter-
natively, this result may be explained by the fact that TNF 
antagonists have been demonstrated to be more effective 
when used as top-down therapy (vs. step-up therapy) in a 
randomized controlled trial setting. In fact, earlier use of 
TNF antagonists was associated with a lower risk of con-
comitant corticosteroid use, TNF antagonist dose escalation, 
discontinuation/switch of TNF antagonists, or CD-related 
surgery [19–21]. As more clinical trial and real-world data 
on newer agents emerge, clinicians will be better positioned 
to make decisions about optimal placement of the various 
advanced therapies. In this context, “big data” and real-
world evidence consortia have become pivotal in changing 
practice, especially for newer agents [16, 17, 22, 23].
Our analysis of the 50 policies included in Yadav et al. 
indicated that, among plans where coverage was known, 
14,698,687 lives were impacted by the lack of consistency in 
coverage between IV and SC ustekinumab (Supplementary 
Data Content 5). These lives would be covered for usteki-
numab IV under medical benefits but not for ustekinumab 
SC under pharmacy benefits, rendering the IV induction/SC 
maintenance regimen recommended in the label impractical 
for clinical use. An additional 957,906 lives may also be 
impacted among those where coverage status of IV formula-
tion is not known (Supplementary Data Content 5). This dis-
cordance between medical and pharmacy benefits presents 
an unnecessary hurdle in real-world practice and potentially 
compromises continuity of care for patients.
The strengths of our analysis include the large number 
of policies (medical: 3185; pharmacy: 6653) and covered 
lives (301,748,186 [medical benefit] and 302,057,543 [phar-
macy benefit]) reviewed, real-time assessment of insurance 
coverage using the MMIT database, and ability to compare 
coverage patterns between biologics and across regions. This 
study is, however, subject to limitations. Data for this study 
were extracted from the MMIT database, and therefore our 
work was based on analyzing insurance policy coverage and 
is subject to the limitations of the policies we reviewed. We 
did not complement these analyses with any survey data 
and did not inquire about the need for a step-up requirement 
for coverage, which could have provided a richer real-world 
perspective on access, a valuable point to consider in further 
studies. Furthermore, access was assessed for the indication 
of UC and CD, and the diagnosis was not confirmed.
In conclusion, contrary to previously published data, this 
analysis found that approximately half of covered lives have 
access to all biological agents (except tofacitinib) as first-
line therapy for UC and CD and two-thirds had access after 
one biologic exposure. IBD management has traditionally 
been divided into 1 mechanism of action and two routes 
of administration. This dichotomy has worked to funnel 
patients into a therapy based on route of administration and 
coverage instead of value and risk-based assessment. With 
the emergence of new therapies, including biosimilars, there 
will be an increased pressure on payers to manage therapies 
and an increased responsibility on physicians to choose the 
most appropriate agent. It is important that modern phy-
sicians understand how to navigate coverage policies and 
advocate to create an individualized treatment pathway for 
each patient.
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